Last week, I got a tip that Joe Biden and his wife Jill would announce their new cancer initiative on Monday that would basically continue the cancer moonshot work the former veep spearheaded in his last year of the White House.
So this would be pretty big news right? Biden + cancer moonshot + new thing.
But then the Congressional Budget Office dropped its report on the Senate health-care bill about 20 minutes before the Bidens went live on Facebook.
However, that event ended up as a kickoff of a full week of events related to cancer research that happened in our nation’s capital this week. The very next day after the Biden announcement, Cancer Support Community held a one-year moonshot anniversary event.
Greg Simon, who headed the White House task force on the moonshot and will now serve as president of the Biden initiative, delivered his keynote address at the Tuesday anniversary event. He took a second to blast the new health-care bill as “a war on the poor.”
Then on Thursday, a bunch of groups held their fifth annual Turning the Tide Against Cancer event.
But apparently not everyone’s a fan. I left Turning the Tide to cover an event on the government’s role in medical innovation organized by conservative think tank American Enterprise Institute. One of the speakers at that panel was former Harvard Medical School Dean Jeffrey S. Flier. While acknowledging, “there’s never been a time in history where we know more and have more capabilities than we do right now,” he cautioned against overpromising that research.
“I don’t like the excessive optimism and spin, moonshot initiatives that make no sense whatsoever,” Flier said, adding, “Things like that make people doubt the honesty of what scientists say. And we don’t want them to doubt us.” You can watch his full remarks here.
Read my full story here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)